MedTrace Logo

Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients

NCT00871845 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 36

Last updated 2018-11-05

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to determine whether obese people do not respond to hepatitis C treatment as well as lean people. This research studies whether obese people will show higher sustained virologic response rate if they lose weight by Orlistat use and dietary and lifestyle modification.

Conditions

Interventions

BEHAVIORAL

Dietary and Lifestyle modification educational sessions

6 sessions of dietary and physical education after which they will start receiving their standard hepatitis C treatment. they will be encouraged to attend up to 12 monthly meetings (along side the monthly visits for their standard viral hepatitis therapy.

Sponsors & Collaborators

  • Hossam Kandil

    lead OTHER

Principal Investigators

  • Hossam M Kandil, MD, PhD · assistant professor of medicine

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-09-30
Primary Completion
2011-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00871845 on ClinicalTrials.gov